Xponance Inc. Purchases 7,517 Shares of UiPath Inc. (NYSE:PATH)

Xponance Inc. increased its holdings in UiPath Inc. (NYSE:PATH) by 12.4% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 68,113 shares of the healthcare company’s stock after purchasing an additional 7,517 shares during the period. Xponance Inc.’s holdings in UiPath were worth $864,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of PATH. Vanguard Group Inc. raised its position in shares of UiPath by 5.6% during the 1st quarter. Vanguard Group Inc. now owns 40,217,936 shares of the healthcare company’s stock valued at $911,741,000 after buying an additional 2,133,078 shares in the last quarter. Pacer Advisors Inc. purchased a new stake in UiPath during the second quarter valued at approximately $69,180,000. Dimensional Fund Advisors LP lifted its stake in shares of UiPath by 37.2% in the 2nd quarter. Dimensional Fund Advisors LP now owns 2,783,571 shares of the healthcare company’s stock valued at $35,296,000 after purchasing an additional 754,519 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of UiPath by 20.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 2,552,921 shares of the healthcare company’s stock worth $32,371,000 after purchasing an additional 439,344 shares during the period. Finally, Ieq Capital LLC increased its position in shares of UiPath by 2.7% during the 2nd quarter. Ieq Capital LLC now owns 1,446,816 shares of the healthcare company’s stock valued at $18,346,000 after purchasing an additional 37,642 shares during the last quarter. Hedge funds and other institutional investors own 62.50% of the company’s stock.

UiPath Price Performance

Shares of UiPath stock opened at $12.80 on Friday. UiPath Inc. has a 1 year low of $10.37 and a 1 year high of $27.87. The stock has a market cap of $7.04 billion, a price-to-earnings ratio of -80.00 and a beta of 0.87. The firm’s 50-day moving average is $12.16 and its two-hundred day moving average is $15.49.

UiPath (NYSE:PATH) last issued its quarterly earnings data on Thursday, September 5th. The healthcare company reported $0.04 EPS for the quarter, topping analysts’ consensus estimates of $0.03 by $0.01. The company had revenue of $316.00 million during the quarter, compared to the consensus estimate of $303.69 million. UiPath had a negative net margin of 8.13% and a negative return on equity of 3.98%. UiPath’s revenue for the quarter was up 10.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.09) earnings per share. On average, equities analysts expect that UiPath Inc. will post -0.23 earnings per share for the current year.

Insider Buying and Selling

In other UiPath news, CFO Ashim Gupta sold 47,671 shares of the business’s stock in a transaction dated Friday, September 13th. The shares were sold at an average price of $12.07, for a total value of $575,388.97. Following the completion of the transaction, the chief financial officer now directly owns 849,917 shares in the company, valued at $10,258,498.19. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 22.37% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on PATH shares. Royal Bank of Canada restated a “sector perform” rating and issued a $16.00 price target on shares of UiPath in a research report on Friday, September 6th. Evercore ISI upped their price target on shares of UiPath from $13.00 to $16.00 and gave the company an “in-line” rating in a report on Friday, September 6th. TD Cowen decreased their price objective on shares of UiPath from $17.00 to $16.00 and set a “hold” rating for the company in a research note on Friday, September 6th. Needham & Company LLC reaffirmed a “hold” rating on shares of UiPath in a research note on Friday, September 6th. Finally, Wells Fargo & Company increased their price target on UiPath from $14.00 to $15.00 and gave the stock an “equal weight” rating in a report on Friday, September 6th. Sixteen research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $17.71.

UiPath Profile

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.